Abstract
Objective:Lung cancer is the most common cause of cancer-related death throughout the world, and the correct choice of treatment based on early diagnosis and staging increases the chance of survival. The present study aims to investigate the contribution of fluorine 18-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) to the management of lung cancer.Methods:In this study, 50 patients who underwent 18F-FDG PET/CT for lung cancer diagnosis and staging between February 2012 and February 2014 were included. The maximum standardized uptake value (SUVmax) of the primary lung lesion along with other findings of 18F-FDG PET/CT and the results of histopathologic and conventional examinations were evaluated retrospectively. The mean survival time of patients was determined, and the findings were compared by using statistical methods.Results:Histopathologic examinations revealed 51 lung cancers in 50 patients. The sensitivity, accuracy and positive predictive value of 18F-FDG PET/CT in detecting primary malignancy were 94%, 94%, 100%, respectively. Adenocarcinoma (n=23, 16.8±13.5) and squamous cell carcinoma (n=15, 17.9±5.6) did not differ significantly regarding their mean SUVmax values (p=0.2). A statistically significant positive correlation (r=0.4) was identified between tumor size and SUVmax value for 51 tumors (p=0.002). The 18F-FDG PET/CT result was true negative in nine, false positive in six, true positive in two, and false negative in four patients who underwent histopathologic evaluation of their lymph nodes. The 18F-FDG PET/CT changed treatment planning in 34% of the patients. No significant relationship was identified between SUVmax value of the tumor and patient survival in patients (p=0.118).Conclusion:The present study concluded that PET/CT was an efficient method in the diagnosis and staging of lung cancer since it provided useful information in addition to conventional methods. It was also observed that PET/CT scanning resulted in a change in therapeutic plans in the majority of patients. However, there was no statistically significant relationship between survival and the SUVmax of the primary mass.
Highlights
Lung cancer is the most frequent malignancy throughout the world since 1985 [1] and the leading cause of cancerrelated death in both men and women [2]
We investigated the contribution of 18F-FDG PET/computed tomography (CT) to lung cancer diagnosis, staging and management, as well as the prognostic and survival effects of the maximum standardized uptake value (SUVmax) of the primary lesion in an 18F-FDG PET/CT
The present study included 50 patients who have been referred to Ege University Faculty of Medicine, Department of Nuclear Medicine between February 2012 and February 2014, and who have undergone 18F-FDG PET/CT scanning for the diagnosing and staging of lung cancer
Summary
Lung cancer is the most frequent malignancy throughout the world since 1985 [1] and the leading cause of cancerrelated death in both men and women [2]. Curative treatment can be offered to lung cancer patients with early diagnosis, in whom computed tomography (CT) is the first diagnostic tool [3]. One of the most important prognostic factors in lung cancer is tumor stage. Proper staging is very important when determining prognosis and choosing appropriate treatment. Fluorine 18-fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) is an effective method for the diagnosis, staging, evaluation of treatment response, follow-up for recurrence and re-staging of lung cancer. We investigated the contribution of 18F-FDG PET/CT to lung cancer diagnosis, staging and management, as well as the prognostic and survival effects of the maximum standardized uptake value (SUVmax) of the primary lesion in an 18F-FDG PET/CT
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
